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ABSTRACT 
Epilepsy is a common neurological condition in women of reproductive age. Being careful in antiepileptic treatment during pregnancy can avoid 
birth defects in off springs. Valproic acid, Carbamazepine, phenytoin, phenobarbital, lamotrigine, oxcarbazepine is some of the antiepileptics 
used even during pregnancy. 
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Introduction 
Epilepsy is a chronic disease experienced by millions and 
distributed in all age groups. Unpredictable seizures which 
cause other health problems are the characteristic of 
Epilepsy. These spectrum conditions have a wide range of 
seizure types. Seizure control is different for different 
patients. On earth between 2.7 and 17.6 per 1000 people are 
suffering with active seizures. Prevalence of epilepsy in 
women of reproductive ageisbetween 0.3% and 0.7%, from 
record based studies [1]. 
If women take precautions, most women with epilepsy can 
give birth to normalbabies.There are increased risks. Higher 
seizure frequency was seen in 15% to 30% of women 
especially in first or third trimester [2]. The seizure 
frequency is unpredictable based on type of seizures. Even in 
case of Catamenial epilepsy. That is seizures with menstrual 
cycle. Hormoneact changes, water and sodium retention, 
stress and decreasing levels of antiepileptic drug are 
underlying causes of higher seizure frequency. Uncontrolled 
seizures may harmful for mother and foetus. Also it is 
obvious that antiepileptic drugs are a class might cause 
major congenitalmalformations and adverse effects of 
cognitive development after prenatal exposure [3]. 
Prior to Pregnancy  
An epileptic patient who taking an AED have a risk of 
hormonal contraceptive failure.The reason behind it 
isinducement of hepatic microsomal enzymes and followed 
by decreasing the production of estradiol[4]. Children born 
to women having epilepsy possess a small risk for the 
inheritance of epilepsy, but the risk is increased for women 
whose epilepsy is genetically originated [5, 6]. Women who 
are seizure free for nine months prior to pregnancy have a 
very high chance of remaining seizure free during pregnancy. 
Several complications are there in pregnancy of an epileptic 
patient. The first one is the fact of potential teratogenicity of 
AED. The next one is women taking AEDs have a greater risk 
of miscarriage. Chance of giving birth to a child having 
congenital malformation is 4-8%. Because these agents can 
be transferred to the foetus via placenta. Also higher drug 
clearance during pregnancy can lower circulating AED 
concentration. It may results in loss of seizure control. 
Earlier studies suggest that folic acid consumptionbefore 
pregnancy can possibly decrease the baby’s risk of birth 
defects [7]. 
Risk of Seizure Medication during Pregnancy 
Risk for the foetus from AED taken during pregnancy is 
primarily that of congenital malformation or birth defects. 
Risk may increase with increasing no of AEDs and also with 
higher dose. The most common malformations are cleft lip, 
cleft palate which can be corrected surgically, cardiac and 
uro-genital defects [8]. Older generation antiepileptics have 
been linked to specific birth defect, such as spina bifida. 
Harmful effects not only manifest as structural defects but 
many include growth restrictions and effects on cognitive 
development and behaviour [9, 10]. 
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Antiepileptic Drug Which Causes Harm 
Data collected from North American AED Pregnancy Registry 
suggests that risk of major malformations for valproate was 
9.3%, for phenobarbital 5.5%, for topiramate 4.2%, for 
carbamazepine 3%, for phenytoin 2.9%, for levetiracetam 
2.4%, and for lamotrigine 2% [11]. 
The data pointing thatlevetiracetam, topiramate and 
lamotrigine were extensively used AED monotherapies 
during the first trimester. Nintytwo percentage of AEDs were 
used for treating epilepsy, six percentage for mood disorders, 
and one percentage for migraine. 
The rate of major malformationriskwas raised with 
increasing valproate dose. Pregnancies with malformations 
had a 1000mg median average daily dose during the first 
trimester .And median average daily dose of pregnancies 
without malformations was 750mg per day. The similar dose 
trend didn’t see in any other AEDs.Both malformed and non-
malformed infants exposed to topiramate, phenobarbital, or 
lamotrigine had same median average daily dose. Also AED 
groups possessing lower risks of major malformations were 
had a burden of higher seizure frequency [11]. 
1. Valproate 
Valproic acid shows an established teratogenicity that is a 
dose dependent risk for malformations [12, 13, 14]. A dose of 
1000 mgwas lead to increased risk [15]. This is generally 
approved, when a woman exposed to valproic acid in first 
trimesterdefinitely leads to neural tube defects with a risk of 
1 per 1000 or 10 per 1000 births. Recent studies also 
suggests an association with oral clefts, limb defects, 
hypospadias and cardiac septal defects.Effects of exposure to 
valproic acid in uterus also leads to autism and 
neurodevelopmental delay. Even with these established 
confirmation for foetal harm,t he reason behind advising 
valproic acid in pregnant women is its effectiveness in the 
treatment of idiopathic generalized epilepsy and, especially, 
juvenile myoclonic epilepsy [16, 17, 18]. 
2. Carbamazepine 
By analysing European prospective studies, the relative risk 
of carbamazepine monotherapy for having major congenital 
malformations was found to be 4.9.While studying the 
frequency of major congenital malformations the most 
commonly reported were cleft palate, neural tube defects 
cardiovascular and urinary tract anomalies. Microcephaly 
and growth retardation were mostly reported with 
carbamazepine monotherapy. Polytherapy combinations 
show highest risk for major congenital malformations. 
Despite of these data the large UK Pregnancy Register study 
showed no increased risk for congenital malformations for 
carbamazepine. Carbamazepine was in association with the 
least risk of major congenital malformationsin all conditions, 
when exposed as a monotherapy. Analysis of data from the 
EURAP epilepsy and pregnancy registry suggests that the 
lowest rate of malformation was with a dose less than 400mg 
per day [17, 18]. 
3. Phenobarbital 
Phenobarbital has been associated with oral clefts. Although 
less common, cardiovascular defects, and urogenital defects 
have also been reported .While going through prospective 
data from the North American AED Pregnancy Registry, out 
of 77 women who treated with Phenobarbital monotherapy, 
the number of confirmed major congenital malformations 
was five. A cleftpalate, cleft lip and four heart defects. The 
report of another two studies point out the increased 
incidence ofcardiac malformations was correlated with in-
utero exposure of phenobarbital. Risk of malformation is 
higher with phenobarbital at all doses [19, 20]. 
4. Phenytoin 
Loughman et al and Hanson et al were described Foetal 
hydantoin syndrome. These infants displayed distal digital 
hypoplasia, mental growth retardation, facial dysmorphism 
and intrauterine growth retardation.Among clinicians and 
scientists the teratogenicity of phenytoin has been well 
recognized.With respect to Australian Pregnancy Registry 
reports major congenital malformation rate for phenytoin is 
4.7%. For phenytoin comparatively a poor number of 
outcomes have reported in other studies. Those studies show 
the range ofmajor congenital malformation rate lying 
between 3.4 and 10.7%. One of the study revealed a greater 
risk for cleft palate with [21, 22]. 
5. Lamotrigine 
The North American AED Pregnancy Registry reports 
exposure to lamotrigine monotherapy in first trimester 
showing greater risk for cleft palate or cleft lip. Major 
congenital malformation rate was found to be 2.3%. The 
major congenital malformation rate of lamotrigine 
monotherapy according to UK pregnancy register was 3.2%. 
In case of Lamotrigine also a positive dose response was 
seen in major congenital malformation rate [22]. The 
researcherscurrently clarified their results to establish that 
the greater risk showed above 400 mg/day in first trimester. 
Controversially, LTG dose and major congenital 
malformation rate did not demonstrated any relation 
between them among 802 exposures reported in the 
International Lamotrigine Pregnancy Registry. Only 1.0% of 
lamotrigine pregnancies committed in serious adverse 
outcomes which includes foetal death and/or major 
congenital malformations.This supportsthe low risk of LTG 
use and which also supported by The UK studywhich 
compared with untreated women having epilepsy [23]. 
6. Oxcarbazepine 
Animal studies have proved increased incidences of foetal 
structural abnormalities and other manifestations of 
developmental toxicity (embryo lethality, growth 
retardation), foetal malformations (craniofacial, 
cardiovascular, and skeletal), embryofoetal death, decreased 
foetal body weight, and maternal toxicity. There is no 
evidence to suggest that teratogenicity in these studies was 
preceded by maternal toxicity. Oxcarbazepine is structurally 
related to carbamazepine, which is considered to be a human 
teratogen. Due to this fact and the results of animal studies, it 
is likely that oxcarbazepine is a human teratogen. 
 New-borns having in utero exposure to oxcarbazepine was 
not given any evidence for an increased risk for 
malformations. However, there is a very small number of 
pregnancies containingin utero exposure to oxcarbazepine. 
There forit is insufficient to draw definitive findings. It is 
necessary to gather additional information from large-scale 
pregnancy registries to establish the safety profile of 
oxcarbazepine both as monotherapy and adjunctive therapy 
during pregnancy [24]. 
7. Levetiracetam 
Several recent studies in a sufficient number of exposed 
pregnancies, establish levetiracetam monotherapy in 
pregnancy possess a decreased risk for congenital 
malformations. If levetiracetam is a part of any polytherapy 
regimen the risk will be increased. However more researches 
are required to manifest the risks of particular antiepileptic 
drug combinations. Women with epilepsy of child bearing 
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age can consider levetiracetam monotherapy as a safer 
alternative for valproate. There is no correlation between 
risk and levetiracetam dose. Not only is its efficacy in focal 
epilepsy but also it a better antiepileptic to use in myoclonic 
epilepsy [25]. 
8. Topiramate 
The North American Antiepileptic Drug (NAAED) Pregnancy 
Registry points out a high risk of oral clefts in infants who 
have an utero exposure to topiramate monotherapy during 
the first trimester of pregnancy. The prevalence of oral clefts 
was 1.4% compared to a prevalence of 0.38% - 0.55% in 
infants exposed to other antiepileptic drugs (AEDs). The 
prevalence is 0.07 % when compared with infants of mothers 
without epilepsy or treatment with other AEDs. According to 
data collected fromNAAED Pregnancy Registry the relative 
risk of oral clefts in pregnancies having topiramate – 
exposure was 21.3, when compared to the risk in a 
background population of women without under treatment. 
The UK Epilepsy and Pregnancy Register also reports higher 
prevalence of oral clefts that is 3.2 % among infants exposed 
to topiramate monotherapy. This is an increase of 16-fold in 
risk compared to the risk in their background population 
that is 0.2%.Topiramate was strongly associated with 
microcephaly [26, 27, 28]. 
Some of the Recently Approved Drugs 
1. Brivaracetam 
There are very less data from human studies regarding effect 
of brivaracetam in fertility, pregnancy and teratogenicity.  
Animal studies, did not shown any effect on male or female 
fertility and no teratogenic potential was demonstrated in 
rat or rabbit models. In rabbits embryo toxicity was seen at 
eight times of maximum recommended dose which is also 
maternal toxic dose. Studies in rats manifest that 
briveracetam cross the placenta and its breast milk 
concentrations areidenticalto plasma concentration of 
mother. As with all women of childbearing potential with 
epilepsy, those taking BRV should receive counselling about 
these issues throughout their management and during 
pregnancy [29]. 
2. Bumetanide 
Bumetanide is belongs to pregnancy category C by the FDA. 
Animal studies did not find any evidence for teratogenicity. 
In rabbits at a dose range of 3.4 to  10 fold of maximum 
recommended therapeutic human dose, a dose-related 
diminishing in litter size and a hike  in resorption rate were 
noted (on a per kg basis). Data from human pregnancy 
studies are not available. Bumetanidemust be given during 
pregnancy only if the benefit outweighs risk [30]. 
3. Eslicarbazepine acetate  
Considering eslicarbazepine acetate exposure in pregnant 
women having epilepsy, the count of normal live birth 
without congenital anomalies was thirty, 18 cases ended in 
abortion and in five cases congenital anomalies were 
identified.In case of abortions 10 were spontaneous and 8 
were induced. But there is no established relationship with 
ESL was confirmed. Concomitant use of ESL with other AEDs 
in 15 pregnancies resulted in 11 spontaneous abortion and 
congenital anomaly [31]. 
Available data are not sufficient to draw conclusions in 
ESLuse through pregnancy. However any particular safety 
issues were not identified, ESL use through pregnancy has to 
be continually monitored and evaluated [31]. 
4. Everolimus 
Animal studies revealed everolimus causes embryofoetal 
toxicities at a dose of 10 mg daily. Toxicities are increased 
post implantation loss, preimplantation, resorption, 
malformation, retarded skeletal development decreased 
number of live foetuses. No controlled data are there in 
human pregnancy. It is unknown whether these drugs induce 
anyfoetal harm or cause for any adverse effects in human 
reproductive system. 
This drug and/or its metabolites cross the placenta in rats. 
When orally administered to rats from early gestation to 
weaning at doses of 1, 3 or 10 mg/kg/day (0.8, 2 and 8 times 
the maximum recommended human dose [MRHD]) was 
associated with foetal and pup deaths at the mid and high 
doses (associated with maternal toxicity). In rabbits, oral 
administration throughout organogenesis revealed embryo 
lethality and maternal toxicity at the mid and high doses 
tested (3 and 10 mg/kg/day). There are limited amounts of 
data in human pregnancy (less than 300 pregnancies). There 
are no controlled data in human pregnancy [32]. 
Conclusion 
Lamotrigine and levetiracetam are two antiepileptic drugs 
which are safe in pregnancy.Almost newer antiepileptics 
drugs didn’t clarified their effects in pregnancy. Data from 
different pregnancy registries has to be continually 
monitored. 
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